Physician profile
Rezwan Islam
NPI 1124054556
$4,222.32
in general payments reported to CMS, 2019-2025
35 companies · $1,205 in 2025
The $1,205 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.74 · 2020: $161 · 2021: $352 · 2022: $110 · 2023: $1,152 · 2024: $1,188 · 2025: $1,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,545.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $809.27 | 2019-2025 | |
| Abbvie INC. | $636.15 | 2021-2025 | |
| Novo Nordisk INC | $553.35 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $469.79 | 2021-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $247.30 | 2021-2025 | Shingrix, Arexvy, Bexsero |
| Dexcom, INC. | $226.45 | 2024-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $168.53 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals LP | $151.65 | 2021-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.88 | 2020-2023 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.49 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $83.75 | 2021-2024 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $81.69 | 2023-2024 | Austedo Xr, Austedo |
| Sunovion Pharmaceuticals INC. | $63.20 | 2019-2020 | |
| Abbott Laboratories | $52.83 | 2023-2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $43.74 | 2024-2025 | Auvelity |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $41.87 | 2020 | |
| Medtronic, INC. | $41.75 | 2022-2023 | Na |
| Phathom Pharmaceuticals, INC. | $37.91 | 2025 | Voquezna |
| Allergan, INC. | $35.63 | 2020 | |
| Tolmar, INC. | $28.87 | 2024 | |
| Amarin Pharma, INC. | $28.10 | 2021 | |
| Edwards Lifesciences Corporation | $23.40 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Vertex Pharmaceuticals Incorporated | $22.54 | 2025 | |
| Averitas Pharma INC. | $21.21 | 2024 | Qutenza |
| Janssen Pharmaceuticals, INC | $19.21 | 2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $17.99 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.38 | 2025 | Trintellix |
| Exact Sciences Corporation | $15.42 | 2025 | Cologuard Collection Kit |
| Lundbeck LLC | $13.93 | 2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $13.80 | 2020 | |
| Sumitomo Pharma America, INC. | $13.68 | 2025 | Gemtesa |
| Impel Pharmaceuticals INC. | $13.45 | 2023 | Trudhesa |
| Xeris Pharmaceuticals, INC. | $13.42 | 2024 | Keveyis |
| Sanofi-Aventis U.S. LLC | $13.15 | 2023 | |
| Genentech USA, INC. | $11.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rezwan Islam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.